-

GE HealthCare announces U.S. FDA 510(k) clearance and CE Mark for Allia Moveo and marks first global installation, advancing precision care in the interventional suite

  • First worldwide Allia Moveo installation at Hôpital Marie-Lannelongue in France highlights progress in redefining interventional care delivery
  • Allia Moveo combines mobility, versatility and AI-powered tools to help clinicians navigate complex minimally invasive procedures with efficiency and accuracy

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company’s bold innovations first unveiled at the Radiological Society of North America’s (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and surgical procedures. Allia Moveo delivers enhanced workflow through a compact, cable-free C-arm system with an intuitive user interface, and AI-powered guidance tools to help clinicians work efficiently and adapt to the spatial constraints of traditional interventional suites.

The Hôpital Marie-Lannelongue in France—a center of excellence in thoracic, vascular and heart surgery, and national reference for complex aortic pathologies—was the first medical center in the world to complete the installation of Allia Moveo. The platform is intended to enable flexible cone-beam computed tomography and support this leading hospital in treating vascular and cardiology diseases. The ergonomic, maneuverable system is tailored to accommodate more patients regardless of body size or weight, with a wide-bore design and effortless table panning to help care teams maintain comfort and access throughout procedures.

“My initial experience with Allia Moveo has been incredible, it’s a real game changer. With Allia Moveo, we had this opportunity to position the system very quickly in any working position that will adapt the best to us,” said Stephan Haulon, M.D., Ph.D., Vascular Surgeon, Head of Aortic Center and Vascular Surgery, Hôpital Marie-Lannelongue (Le Plessis-Robinson), part of the Fondation Hôpital Saint-Joseph, Paris, France*. “One of the major milestones of this new system is having access to the reconstruction of the cone beam CT with CleaRecon DL, which is AI driven and gives you much better image quality.”

As interventional procedures grow more demanding, clinicians need imaging solutions that deliver clear insights and optimize workflows. During minimally invasive interventions involving multiple users, the ability to increase procedural confidence can depend on advanced imaging systems that can be positioned easily and quickly, capture high quality images and integrate with other technology - all while operating at a volume quieter than a normal conversation. Allia Moveo was created with clinicians to address these challenges by delivering an easy-to-use, high-performance system, built to enhance fluidity when space is at a premium.

“With Allia Moveo, we’re elevating the clinician experience, removing complexity, accelerating workflow, and enabling greater control during procedures,” said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare. “We are excited to collaborate with leading experts at Hôpital Marie-Lannelongue on the first installation of this system, which is a defining step forward for care in the interventional suite, and a testament to our shared commitment to advancing meaningful innovation with the goal of supporting better outcomes for care teams and the patients they treat.”

Allia Moveo is equipped with advanced 3D imaging solutions that help clinicians visualize anatomy with confidence and make informed decisions, including:

  • CleaRecon DLi, AI-driven technology that removes streak artifacts caused by the pulsatile nature of blood flow in the arteries, delivering clearer, reliable images.
  • Motion Freeze, a tool that helps offset involuntary respiratory motion artifact to improve image clarity.
  • Metallic Artifact Reduction, designed to reveal anatomic details obscured by metal artifacts.
  • Augmented guidance solutions including ASSIST advanced clinical applications portfolio—offering augmented guidance for complex procedures—along with compatibility with other GE HealthCare and third-party systems.

Following the first global installation of Allia Moveo at Hôpital Marie-Lannelongue, Houston’s Baylor St. Luke’s Medical Center, a member of CommonSpirit, marked the first installation in the United States.

“We are honored to be the first hospital in the United States to install Allia Moveo, and proud to help advance the next generation of interventional care,” said Brad Lembke, MD, President of Baylor St. Luke’s Medical Center**. “This innovative platform enhances how our clinicians navigate complex minimally invasive procedures by improving mobility, image clarity, and workflow efficiency. It strengthens our ability to deliver precise, patient-centered care while supporting our teams with technology designed for the evolving demands of modern interventional medicine.”

This product may not be available in all regions, contact your GE HealthCare sales representative for more information. To learn more about Allia Moveo, visit https://www.gehealthcare.com/products/image-guiding-solutions/allia-moveo.

*Dr. Stephan Haulon is a paid consultant for GEHC. The statements by Dr. Stephan Haulon described here are based on their own opinions and on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist, i.e. hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results.

**The statements by Dr. Brad Lembke, described here are based on their own opinions and on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist, i.e. hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

i CleaRecon DL, designed to be used with Allia systems, is an option in 3DXR designed to be used with Allia systems and requires AW workstation with Volume Viewer. May not be available in all countries.

Contacts

GE HealthCare Media Contact:
Eric Tatro
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

GE HealthCare Technologies Inc.

NASDAQ:GEHC

Release Versions

Contacts

GE HealthCare Media Contact:
Eric Tatro
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

More News From GE HealthCare Technologies Inc.

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the I...

GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations

CHICAGO--(BUSINESS WIRE)--At ACC.26, GE HealthCare (Nasdaq: GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey. According to t...

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonova™ Spectra,i an innovative photon‑counting computed tomography (PCCT) solution powered by the company’s novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spec...
Back to Newsroom